- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06212245
A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
January 8, 2024 updated by: Hansoh BioMedical R&D Company
An Open-label Single-arm Clinical Study to Assess the Efficacy and Safety of Inebilizumab in Chinese Adult Patients With Neuromyelitis Optica Spectrum Disorders (NMOSD)
To assess the efficacy and safety of Inebilizumab in Chinese adult patients with neuromyelitis optica spectrum disorders.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
33
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- IRB of Beijing Tiantan Hospital, Capital Medical University
-
Contact:
- Lingling Xu
- Phone Number: 010-59975692
- Email: ttyyirb@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients who have comprehensive understanding of the study content, process and possible adverse reactions, and sign the informed consent forms voluntarily
- Men and women 18 years or older
- Patients with NMOSD diagnosed according to the definition in the Guidelines for the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders in China
- Patients with positive serum anti-AQP4-IgG results at screening
- A documented history of one or more NMOSD acute relapses that required rescue therapy within the last year, or 2 or more NMOSD acute relapses that required rescue therapy within 2 years prior to screening
- Patients with EDSS score of ≤ 7.5 points
- Patients who and whose sexual partner agree to take highly effective method of contraception from screening
Exclusion Criteria:
Patients who have received any of the following treatments at any time prior to randomization:
- Monoclonal antibodies against CD52: such as alemtuzumab, etc.
- Total lymphoid irradiation
- Bone marrow transplant
- T-cell vaccination therapy
- Receipt of rituximab or other B-cell depleting agents (e.g., Belimumab, Telitacicept) within 6 months prior to screening, unless the patient has B-cell counts above the LLN according to the central laboratory;
- Receipt of rituximab or other B-cell depleting agents (e.g., Belimumab, Telitacicept) within 6 months prior to screening, unless the patient has B-cell counts above the LLN according to the central laboratory;
- Patients who have received intravenous injection of immunoglobulin (IVIG) within 1 month prior to randomization;
- Patients who have received immunosuppressant therapy (e.g., cyclophosphamide, methotrexate, mitoxantrone, ciclosporin A, etc.) and biologics (satralizumab, natalizumab, tocilizumab, eculizumab, etc.) within 3 months or 5 half-lives of such drugs (whichever is longer) before randomization;
- Any concomitant disease other than NMOSD that required treatment with oral or IV steroids at doses > 20 mg/day for > 21 days within the 6 months prior to screening;
- Concurrent/previous enrollment in another clinical study involving an investigational treatment within 4 weeks or 5 published half-lives of the investigational treatment, whichever is the longer, prior to enrollment;
- Severe drug allergic history or anaphylaxis to two or more food products or medicine (including known sensitivity to acetaminophen/paracetamol, diphenhydramine or equivalent antihistamine, and methylprednisolone or equivalent glucocorticoid); Known history of allergy or reaction to any component of the investigational product formulation or history of anaphylaxis following any biologic therapy;
- Patients with evidence of alcohol, drug, or chemical abuse, or with history of such abuse within 1 year prior to randomization;
- Female patients who are lactating or pregnant, or plan to become pregnant at any time from signing the informed consent through the study plus 6 months following last dose of investigational product;
- Patients with clinically significant serious active or chronic viral infection, or bacterial infection within 60 days prior to randomization, which requires treatment with anti-infective agents or hospitalization, or might pose an additional risk to the patient in the opinion of the investigator;
- Patients with known history or underlying disease of primary immunodeficiency (congenital or acquired), such as human immunodeficiency virus (HIV) infection or splenectomy, which predisposes the patient to infection;
- Confirmed positive serology results of hepatitis B/C at screening
- Patients with history of malignancy, except squamous or basal cell carcinoma of skin that has been successfully treated with documented success of curative therapy > 3 months prior to randomization;
- Any other conditions that, in the opinion of the investigator, are not suitable for participating in the clinical study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Inebilizumab
Participants will receive IV inebilizumab 300 mg
|
Participants will receive IV inebilizumab 300 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants with NMOSD attack determined by the investigator
Time Frame: Day 1 (Baseline) through Day 197
|
The NMOSD attack is defined as the presence of new or worsening symptom(s) related to NMOSD that meet at least one of the 18 protocol-defined attack criteria.
These criteria were developed in conjunction with a panel of disease experts and with Food and Drug Administration input, and were intended to be clinically meaningful, objective, quantifiable, and able to be used worldwide.
|
Day 1 (Baseline) through Day 197
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants with NMOSD attack determined by the investigator
Time Frame: Day 1 (Baseline) through Day 379
|
The NMOSD attack is defined as the presence of new or worsening symptom(s) related to NMOSD that meet at least one of the 18 protocol-defined attack criteria.
These criteria were developed in conjunction with a panel of disease experts and with Food and Drug Administration input, and were intended to be clinically meaningful, objective, quantifiable, and able to be used worldwide.
|
Day 1 (Baseline) through Day 379
|
Percentage of Participants With Worsening in Expanded Disability Severity Scale (EDSS) Score
Time Frame: Day 1 (Baseline) through Day 379
|
TEDSS and its associated functional system (FS) score provide a system for quantifying disability and monitoring changes in the level of disability over time.
EDSS is a scale for assessing neurologic impairment in multiple sclerosis (MS).
It consists of 7 FS (visual FS, brainstem FS, pyramidal FS, cerebellar FS, sensory FS, bowel and bladder FS, and cerebral FS) which are used to derive EDSS score ranging from 0 (normal neurological exam) to 10 (death from MS).
A negative change from baseline indicates improvement.
A participant was considered to have a worsening in overall EDSS score of at least 2 if baseline EDSS score was 0, or at least 1 point if baseline EDSS score is 1 to 5, or at least 0.5 point if baseline EDSS score is 5.5 or more.were
measured by MRI of the brain, optic nerve, and spinal cord.
|
Day 1 (Baseline) through Day 379
|
Cumulative Number of Active Magnetic Resonance Imaging (MRI) Lesions
Time Frame: Day 1 (Baseline) through Day 379
|
The number of new gadolinium-enhancing lesions and new or enlarging T2 lesions were measured by MRI of the brain, optic nerve, and spinal cord.
|
Day 1 (Baseline) through Day 379
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Laboratory measurements as well as their changes or shift as assessed by CTCAE v5.0
Time Frame: Day 1 (Baseline) through Day 379
|
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Serious adverse event is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention.
|
Day 1 (Baseline) through Day 379
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
February 25, 2024
Primary Completion (Estimated)
December 25, 2024
Study Completion (Estimated)
June 25, 2025
Study Registration Dates
First Submitted
December 15, 2023
First Submitted That Met QC Criteria
January 8, 2024
First Posted (Estimated)
January 18, 2024
Study Record Updates
Last Update Posted (Estimated)
January 18, 2024
Last Update Submitted That Met QC Criteria
January 8, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HS-20091-401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuromyelitis Optica Spectrum Disorders
-
Jagannadha R AvasaralaTerminatedMultiple Sclerosis | Optic Neuritis | Neuromyelitis Optica Spectrum Disorder Attack | Neuromyelitis Optica Spectrum Disorder Relapse | Neuromyelitis Optica Spectrum Disorder ProgressionUnited States
-
MedImmune LLCCompletedNeuromyelitis Optica and Neuromyelitis Optica Spectrum DisordersUnited States, Czechia, Thailand, Germany, Korea, Republic of, Israel, New Zealand, Spain, Taiwan, Japan, Turkey, Hungary, Bulgaria, Mexico, Russian Federation, Colombia, Peru, Poland, Estonia, South Africa, Canada, Australia, Hong... and more
-
Feng JinzhouNot yet recruitingNeuromyelitis Optica Spectrum Disorders
-
BiocadRecruitingNeuromyelitis Optica Spectrum DisordersRussian Federation
-
First Affiliated Hospital of Fujian Medical UniversityThird Affiliated Hospital, Sun Yat-Sen University; MyBiotech Co. Ltd, ChinaCompletedNeuromyelitis Optica Spectrum DisordersChina
-
Tianjin Medical University General HospitalCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum DisordersChina
-
Fu-Dong ShiCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum Disorders | Devic's DiseaseChina
-
Reistone Biopharma Company LimitedCompletedNeuromyelitis Optica Spectrum DisordersChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityNanfang Hospital of Southern Medical University; Second Affiliated Hospital... and other collaboratorsUnknownNeuromyelitis Optica Spectrum DisordersChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityZhongshan Ophthalmic Center, Sun Yat-sen University; Southern Medical University...UnknownMycophenolate Mofetil | Neuromyelitis Optica Spectrum Disorders | Efficacy and Safety
Clinical Trials on Inebilizumab
-
Horizon Therapeutics Ireland DACRecruitingNeuromyelitis Optica Spectrum DisorderUnited Kingdom, Brazil, Serbia, United States, Canada, France, Poland, Spain, Sweden, Argentina, Netherlands
-
Mitsubishi Tanabe Pharma CorporationRecruiting
-
Horizon Therapeutics Ireland DACRecruitingPregnancy Related | Neuromyelitis Optica Spectrum DisorderUnited States
-
AmgenActive, not recruitingIgG4 Related DiseasePoland, Spain, United States, Argentina, Australia, Canada, China, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Mexico, Netherlands, Sweden, Turkey, United Kingdom
-
AmgenActive, not recruitingMyasthenia GravisUnited States, Argentina, Belarus, Brazil, Canada, China, Denmark, France, Germany, India, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Taiwan, Turkey, Ukraine
-
Horizon Therapeutics Ireland DACNot yet recruitingNeuromyelitis Optica Spectrum Disorder
-
MedImmune LLCCompletedNeuromyelitis Optica and Neuromyelitis Optica Spectrum DisordersUnited States, Czechia, Thailand, Germany, Korea, Republic of, Israel, New Zealand, Spain, Taiwan, Japan, Turkey, Hungary, Bulgaria, Mexico, Russian Federation, Colombia, Peru, Poland, Estonia, South Africa, Canada, Australia, Hong... and more
-
Viela BioWithdrawnHighly Sensitized Patients on Waiting List for Kidney TransplantationUnited States
-
University of UtahRecruitingEncephalitis | Autoimmune EncephalitisUnited States, Netherlands, Spain
-
Xuanwu Hospital, BeijingJiangsu Hansoh Pharmaceutical Co., Ltd.Not yet recruitingNeuromyelitis Optica Spectrum Disorder